Applied Micro Circuits (AMCC) Inactive 10-Q3 Nov 152016 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 26, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED MICRO CIRCUITS CORP
Entity Central Index Key	711,065
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		82,835,764

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015	[1]
Current assets:
Cash and cash equivalents	$ 21,075	$ 36,495
Short-term investments	54,425	38,863
Accounts receivable, net	12,624	12,407
Inventories	20,382	23,514
Other current assets	15,545	16,840
Total current assets	124,051	128,119
Property and equipment, net	14,415	16,749
Goodwill	11,425	11,425
Other assets	1,449	2,570
Total assets	151,340	158,863
Current liabilities:
Accounts payable	12,128	13,896
Accrued payroll and other accrued liabilities	3,968	3,770
Veloce accrued liability	3,231	5,742
Other accrued liabilities	8,317	7,644
Deferred revenue	392	415
Total current liabilities	28,036	31,467
Non-current liabilities	$ 4,356	$ 4,291
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.01 par value: Authorized shares - 2,000, none issued and outstanding	$ 0	$ 0
Common stock, $0.01 par value: Authorized shares - 375,000 at September 30, 2015 and March 31, 2015; Issued and outstanding shares - 82,836 at September 30, 2015 and 80,816 at March 31, 2015	828	808
Additional paid-in capital	6,046,111	6,032,604
Accumulated other comprehensive loss	(9,705)	(7,486)
Accumulated deficit	(5,918,286)	(5,902,821)
Total stockholders’ equity	118,948	123,105
Total liabilities and stockholders’ equity	$ 151,340	$ 158,863

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Mar. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	2,000,000	2,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	375,000,000	375,000,000
Common stock, shares issued (shares)	82,836,000	80,816,000
Common stock, shares outstanding (shares)	82,836,000	80,816,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net revenues	$ 39,743	$ 40,945	$ 77,556	$ 91,217
Cost of revenues	17,758	17,716	34,564	37,973
Gross profit	21,985	23,229	42,992	53,244
Operating expenses:
Research and development	22,411	24,711	44,028	57,916
Selling, general and administrative	8,373	7,919	17,137	16,977
Amortization of purchased intangible assets	0	42	0	104
Restructuring	15	(110)	111	1,101
Total operating expenses	30,799	32,562	61,276	76,098
Operating loss	(8,814)	(9,333)	(18,284)	(22,854)
Realized gain on short-term investments and interest income, net	257	393	1,876	729
Other income (expense), net	8	(2,505)	33	(2,526)
Loss before income taxes	(8,549)	(11,445)	(16,375)	(24,651)
Income tax (benefit) provision	(488)	272	(910)	131
Net loss	$ (8,061)	$ (11,717)	$ (15,465)	$ (24,782)	[1]
Basic and diluted net loss per share (in dollars per share)	$ (0.10)	$ (0.15)	$ (0.19)	$ (0.32)
Shares used in calculating basic and diluted net loss per share (in shares)	82,176	78,487	81,680	78,202

[1]	The Statement of Cash Flows for the six months ended September 30, 2014 reflects an immaterial revision to correct outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities. As a result, net cash used for operating activities increased by $0.3 million and net cash used for investing activities decreased by the corresponding amount.

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net loss		$ (8,061)	$ (11,717)	$ (15,465)	$ (24,782)	[1]
Other comprehensive loss, net of tax:
Unrealized (loss) gain on investments	[2]	(196)	(171)	(1,849)	296
Loss on foreign currency translation		(233)	(127)	(370)	(215)
Other comprehensive (loss) gain, net of tax		(429)	(298)	(2,219)	81
Total comprehensive loss		$ (8,490)	$ (12,015)	$ (17,684)	$ (24,701)

[1]	The Statement of Cash Flows for the six months ended September 30, 2014 reflects an immaterial revision to correct outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities. As a result, net cash used for operating activities increased by $0.3 million and net cash used for investing activities decreased by the corresponding amount.
[2]	The amounts reclassified from accumulated other comprehensive loss and recorded in net realized gain on short-term investments and interest income, net in the Condensed Consolidated Statement of Operations relating to sale of short-term investments were $0.1 million and $1.5 million for the three and six months ended September 30, 2015, respectively and zero for the three and six months ended September 30, 2014. Refer to Note 2, Certain Financial Statement Information, to the Condensed Consolidated Financial Statements for additional details.

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Reclassification adjustment from AOCI to earnings, short term investments	$ 100,000	$ 0	$ 1,500,000	$ 0

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2015		Sep. 30, 2014	[1]
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Net loss	$ (15,465)		$ (24,782)
Depreciation	3,671		4,376
Amortization of purchased intangible assets	0		104
Stock-based compensation expense	12,026		9,446
Veloce acquisition consideration	0		7,140
(Gain) loss on short-term Investments and other, net	(1,587)		22
Impairment of a strategic investment	0		2,500
Tax effect on other comprehensive loss	0		(84)
Changes in operating assets and liabilities:
Accounts receivable	(217)		7,297
Inventories	3,149		1,334
Other assets	2,109		600
Accounts payable	(2,358)		(12,094)
Accrued payroll and other accrued liabilities	170		(2,589)
Veloce accrued liability	(90)		(7,499)
Deferred revenue	(23)		(166)
Net cash provided by (used for) operating activities	1,385		(14,395)
Investing activities:
Proceeds from sales and maturities of short-term investments	47,847		1,920
Purchases of short-term investments	(63,702)		(2,069)
Proceeds from sale of property and equipment	31		1
Purchases of property and equipment	(807)		(7,020)
Proceeds from sale of TPack	0		3,353
Net cash used for investing activities	(16,631)		(3,815)
Financing activities:
Proceeds from issuance of common stock	1,245		1,863
Funding of restricted stock units withheld for taxes	(1,419)		(1,246)
Net cash (used for) provided by financing activities	(174)		617
Net decrease in cash and cash equivalents	(15,420)		(17,593)
Cash and cash equivalents at beginning of year	36,495	[2]	71,539
Cash and cash equivalents at end of period	21,075		53,946
Supplementary cash flow disclosures:
Cash paid for income taxes	$ 328		$ 425

[1]	The Statement of Cash Flows for the six months ended September 30, 2014 reflects an immaterial revision to correct outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities. As a result, net cash used for operating activities increased by $0.3 million and net cash used for investing activities decreased by the corresponding amount.
[2]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) $ in Thousands	6 Months Ended
	Sep. 30, 2014USD ($)
Prior Period Adjustments Restatement [Line Items]
Net cash provided by operating activities	$ (14,395)	[1]
Net cash used for investing activities	3,815	[1]
Restatement Adjustment [Member]
Prior Period Adjustments Restatement [Line Items]
Net cash provided by operating activities	300
Net cash used for investing activities	$ 300

[1]	The Statement of Cash Flows for the six months ended September 30, 2014 reflects an immaterial revision to correct outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities. As a result, net cash used for operating activities increased by $0.3 million and net cash used for investing activities decreased by the corresponding amount.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Condensed Consolidated Financial Statements include all the accounts of Applied Micro Circuits Corporation (the "Company") and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company prepared the accompanying unaudited Condensed Consolidated Financial Statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In management’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to fairly present the Company's financial position, results of operations and cash flows. Interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the Consolidated Financial Statements and notes thereto in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2015. Use of Estimates The preparation of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its: • capitalized mask sets including their useful lives, which affect cost of goods sold and property and equipment or Research and Development ("R&D") expenses, if not capitalized; • inventory valuation, warranty liabilities and revenue reserves, which affect cost of sales, gross margin, and revenues; • allowance for doubtful accounts, which affects operating expenses; • unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affect interest income (expense), net; • valuation of other long-lived assets and goodwill, which affects depreciation and impairment of long-lived assets, impairment of goodwill and apportionment of goodwill related to divestitures; • potential costs of litigation, which affect operating expenses; • valuation of deferred income taxes, which affects income tax expense (benefit); and • stock-based compensation, which affects gross margin and operating expenses. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and actual results, future results of operations will be affected. New Accounting Pronouncements In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2014-15, "Presentation of Financial Statements-Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern", which requires an entity's management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or within one year after the date that the financial statements are available to be issued, when applicable. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating this new standard, and after adoption, it will incorporate this guidance in its assessment of going concern. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted but adoption on the original effective date is permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures.

Certain Financial Statement Inf

Certain Financial Statement Information	6 Months Ended
Certain Financial Statement Information	Sep. 30, 2015
Certain Financial Statement Information [Abstract]
CERTAIN FINANCIAL STATEMENT INFORMATION	CERTAIN FINANCIAL STATEMENT INFORMATION Accounts receivable, net: September 30, March 31, (In thousands) Accounts receivable $ 12,909 $ 12,709 Less: allowance for bad debts (285 ) (302 ) $ 12,624 $ 12,407 Inventories: September 30, March 31, (In thousands) Finished goods $ 10,807 $ 15,310 Work in process 6,090 5,377 Raw materials 3,485 2,827 $ 20,382 $ 23,514 Other current assets: September 30, March 31, (In thousands) Prepaid expenses $ 13,335 $ 14,847 Executive deferred compensation assets 942 1,004 Other 1,268 989 $ 15,545 $ 16,840 Property and equipment: Useful Life September 30, March 31, (In years) (In thousands) Machinery and equipment 3-5 $ 37,795 $ 37,286 Leasehold improvements 1-5 7,533 9,909 Computers, office furniture and equipment 3-5 33,904 32,902 79,232 80,097 Less: accumulated depreciation (64,817 ) (63,348 ) $ 14,415 $ 16,749 Goodwill: September 30, March 31, (In thousands) Goodwill $ 11,425 $ 11,425 Other assets: September 30, March 31, (In thousands) Non-current portion of prepaid expenses $ 854 $ 1,974 Other 595 596 $ 1,449 $ 2,570 Other accrued liabilities: September 30, March 31, (In thousands) Employee related liabilities $ 1,415 $ 1,454 Executive deferred compensation 984 1,025 Income taxes 304 1,311 Other 5,614 3,854 $ 8,317 $ 7,644 Short-term investments: The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands): September 30, 2015 March 31, 2015 Amortized Cost Gross Unrealized Estimated Fair Value Amortized Cost Gross Unrealized Estimated Fair Value Gains Losses Gains Losses Cash $ 16,224 $ — $ — $ 16,224 $ 33,936 $ — $ — $ 33,936 Cash equivalents 4,851 — — 4,851 2,559 — — 2,559 U.S. Treasury securities and agency bonds 23,813 40 — 23,853 1,230 — — 1,230 Corporate bonds 24,515 69 (17 ) 24,567 10,772 28 (6 ) 10,794 Asset-backed securities 4,633 2 (1 ) 4,634 — 15 — 15 Municipal bonds 1,353 2 — 1,355 — — — — Mutual funds — — — — 24,895 1,955 (59 ) 26,791 Preferred stock 5 11 — 16 11 22 — 33 $ 75,394 $ 124 $ (18 ) $ 75,500 $ 73,403 $ 2,020 $ (65 ) $ 75,358 Reported as: Cash and cash equivalents $ 21,075 $ 36,495 Short-term investments available-for-sale 54,425 38,863 $ 75,500 $ 75,358 The established guidelines for measuring fair value and expanded disclosures regarding fair value measurements are defined as a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 — Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 — Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands): September 30, 2015 March 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash $ 16,224 $ — $ — $ 16,224 $ 33,936 $ — $ — $ 33,936 Cash equivalents 4,851 — — 4,851 2,559 — — 2,559 U.S. Treasury securities and agency bonds 23,853 — — 23,853 1,230 — — 1,230 Corporate bonds — 24,567 — 24,567 — 10,794 — 10,794 Asset-backed securities — 4,634 — 4,634 — 15 — 15 Municipal bonds 1,355 — — 1,355 — — — — Mutual funds — — — — 26,791 — — 26,791 Preferred stock — 16 — 16 — 33 — 33 $ 46,283 $ 29,217 $ — $ 75,500 $ 64,516 $ 10,842 $ — $ 75,358 There were no significant transfers in and out of Level 1 and Level 2 fair value measurement categories during the three and six months ended September 30, 2015 and 2014 . The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds, asset-backed securities and municipal bonds, by contractual maturity (in thousands): September 30, 2015 Cost Estimated Fair Value Less than 1 year $ 11,574 $ 11,583 Mature in 1 – 2 years 31,700 31,730 Mature in 3 – 5 years 11,040 11,096 Mature after 5 years — — $ 54,314 $ 54,409 The following is a summary of gross unrealized losses (in thousands): As of September 30, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses U.S. Treasury securities and agency bonds $ 1,579 $ — $ — $ — $ 1,579 $ — Corporate bonds 6,617 (17 ) — — 6,617 (17 ) Asset-backed securities 1,404 (1 ) — — 1,404 (1 ) $ 9,600 $ (18 ) $ — $ — $ 9,600 $ (18 ) As of March 31, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate bonds $ 878 $ (6 ) $ — $ — $ 878 $ (6 ) Mutual funds 14,592 (17 ) 475 (42 ) 15,067 (59 ) $ 15,470 $ (23 ) $ 475 $ (42 ) $ 15,945 $ (65 ) Other-Than-Temporary Impairment Based on an evaluation of securities that have been in a continuous loss position, the Company did not recognize any other-than-temporary impairment charges for the three and six months ended September 30, 2015 and 2014 . The Company considered various factors which included a credit and liquidity assessment of the underlying securities and the Company’s intent and ability to hold the underlying securities until the estimated date of recovery of its amortized cost. Warranty reserves: The Company's products typically carry a one-year warranty. The Company establishes reserves for estimated product warranty costs at the time revenue is recognized. Although the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates, use of materials, and service delivery costs incurred in correcting any product failure. Should actual product failure rates, use of materials or service delivery costs differ from the Company’s estimates, additional warranty reserves could be required, which could reduce its gross margin. The following table summarizes warranty reserve activities (in thousands): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Beginning balance $ 222 $ 177 $ 194 $ 199 Additions during the period 72 6 129 — Settlements and expirations (25 ) (8 ) (53 ) (23 ) Change in estimates (9 ) — (10 ) (1 ) Ending balance $ 260 $ 175 $ 260 $ 175 Realized gain on short-term investments and interest income, net (in thousands): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Net realized gain on short-term investments $ 127 $ 5 $ 1,557 $ — Interest income, net 130 388 319 729 $ 257 $ 393 $ 1,876 $ 729 Net loss per share: Shares used in basic net loss per share are computed using the weighted average number of common shares outstanding during each period. Shares used in diluted net loss per share include the dilutive effect of common shares potentially issuable upon the exercise of stock options and vesting of restricted stock units ("RSUs"). The reconciliation of shares used to calculate basic and diluted net loss per share consists of the following (in thousands, except per share data): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Net loss $ (8,061 ) $ (11,717 ) $ (15,465 ) $ (24,782 ) Shares used in net loss per share computation: Weighted average common shares outstanding, basic 82,176 78,487 81,680 78,202 Net effect of dilutive common share equivalents — — — — Weighted average common shares outstanding, diluted 82,176 78,487 81,680 78,202 Basic and diluted net loss per share $ (0.10 ) $ (0.15 ) $ (0.19 ) $ (0.32 ) The effect of dilutive securities (comprised of options and RSUs) totaling 3.5 million and 3.6 million shares for the three and six months ended September 30, 2015 , respectively, and 1.0 million and 1.2 million shares for the three and six months ended September 30, 2014 , respectively, has been excluded from the diluted net loss per share computation since the Company incurred net losses in the periods presented and their effect would be antidilutive.

Restructuring Charges

Restructuring Charges	6 Months Ended
Restructuring Charges	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
RESTRUCTURING CHARGES	RESTRUCTURING CHARGES In January 2015, the Company implemented a restructuring plan to reorganize its operations and reduce its workforce and related operating expenses in order to increase its operating efficiencies. This plan eliminated approximately 40 positions, or approximately 7% , of headcount. The Company completed this plan at the end of the quarter ended September 30, 2015 and incurred total restructuring charges of $4.2 million . The following table sets forth a summary of restructuring activities related to the Company's restructuring plan described above (in thousands): Workforce Reduction Operating Lease Commitments Other Total Liability, March 31, 2015 $ 449 $ 113 $ 15 $ 577 Restructuring charges 109 — 2 111 Cash payments (270 ) (41 ) (9 ) (320 ) Non-cash items (14 ) 12 — (2 ) Liability, September 30, 2015 $ 274 $ 84 $ 8 $ 366

Veloce

Veloce	6 Months Ended
Veloce	Sep. 30, 2015
Business Combinations [Abstract]
VELOCE	VELOCE In June 2012, the Company completed its acquisition of Veloce Technologies, Inc. ("Veloce") which had been developing specific ARM-based technology for the Company. The total purchase consideration for Veloce was $178.5 million , the payment of which has been subject to the completion of certain development milestones and vesting requirements. For accounting purposes, the costs incurred in connection with the development milestones relating to Veloce are considered compensatory and are recognized as R&D expense in the Condensed Consolidated Statements of Operations. Veloce completed the milestones as of March 31, 2014 and the total consideration of $178.5 million has been recognized as R&D expense as of March 31, 2015. The following table summarizes the cash payment and stock issuance activities during the three and six months ended September 30, 2015 and 2014 as part of the above arrangement (in thousands): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Cash payments $ 25 $ 1,116 $ 90 $ 7,499 Value of common stock issued 1,947 281 2,868 615 Total payments $ 1,972 $ 1,397 $ 2,958 $ 8,114 Shares of common stock issued 354 38 517 77 As of September 30, 2015 , $171.9 million of the total Veloce consideration has been paid and the Company expects that an additional $1.1 million will be paid in cash and stock by December 31, 2015 . The $171.9 million paid to date includes $89.4 million in cash and the issuance of 11.2 million shares of common stock valued at $82.5 million . The consideration not yet paid of $6.6 million as of September 30, 2015 can be settled in cash or common stock (or a combination of cash and stock) at the Company's election and is classified as long-term if payments of the consideration are expected to occur beyond a 12 month period.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Sep. 30, 2015
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stock Options The Company has granted stock options to employees and non-employee directors under several plans. These option plans include two stockholder-approved plans (1992 Equity Incentive Plan and 2011 Equity Incentive Plan) and one plan not approved by stockholders (2000 Equity Incentive Plan). Certain other outstanding options were assumed through the Company’s various acquisitions. A summary of the Company's stock option activities and related information during the six months ended September 30, 2015 is as follows: Number of Shares (thousands) Weighted Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value (millions) Outstanding at the beginning of the year 1,794 $ 9.15 Granted — — Exercised (25 ) $ 5.23 — (1 ) Cancelled (99 ) $ 10.65 Outstanding at the end of the period 1,670 $ 9.12 1.4 $ — (2 ) Vested and expected to vest at the end of the period 1,670 $ 9.12 1.4 $ — (2 ) Vested and exercisable at the end of the period 1,670 $ 9.12 1.4 $ — (2 ) (1) The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. (2) The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of September 30, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $5.31 per share on September 30, 2015 . Restricted Stock Units The Company has granted RSUs to employees and non-employee directors pursuant to its 1992 Equity Incentive Plan and 2011 Equity Incentive Plan. RSUs are share awards that, upon vesting, will deliver to the holder shares of the Company’s common stock. Generally, RSUs vest ratably on a quarterly basis over four years from the date of grant. For new employee grants, 25% of RSUs will vest on the first year anniversary of the grant date and the remaining shares will vest ratably on a quarterly basis. In May and November 2013 and May and October 2014, the Compensation Committee (the "Committee") authorized market-performance based RSUs ("MSUs"). The MSUs will be earned, if at all, based on the Company's Total Shareholder Return (“TSR”) compared to that of the Standard & Poor's Depositary Receipts (the "SPDR") S&P Semiconductor Index ("Index”) over a two -year performance period for half of the MSU award and a three -year performance period for the remaining half of the MSU award. The MSUs will vest between ranges of 0% and 150% based on the Company's relative TSR compared to the Index. Total grant-date fair value of these MSUs was $4.5 million , of which $1.3 million expired unvested as of September 30, 2015 . In March 2015, the Committee authorized an incentive compensation program with respect to fiscal 2016 (the “Incentive Compensation Program”). Total value of the Incentive Compensation Program was $6.7 million as of September 30, 2015 , of which $3.3 million was recognized during the six months ended September 30, 2015 . Awards under the Incentive Compensation Program pay out in fully vested shares of common stock on a quarterly basis over a one -year period. In May 2015 , the Committee authorized an annual incentive compensation plan with respect to fiscal 2016 (the “FY2016 Short-Term Incentive Plan”). The FY2016 Short-Term Incentive Plan will pay out based on our actual performance as measured against revenue. The award payouts range from 50% to 150% of the pre-established target level based on the Company's actual performance for fiscal 2016. Awards under the FY2016 Short-Term Incentive Plan will be payable, if at all, in fully vested shares of common stock or cash on May 16, 2016. RSU activities during the six months ended September 30, 2015 is set forth below (in thousands): Number of Shares Outstanding at the beginning of the year 4,328 Awarded 1,474 Vested (1,462 ) Cancelled (342 ) Outstanding at the end of the period 3,998 The weighted average remaining contractual term for the RSUs outstanding as of September 30, 2015 was 1.2 years. As of September 30, 2015 , the aggregate pre-tax intrinsic value of RSUs outstanding was $21.2 million . The aggregate pretax intrinsic value was calculated based on the closing price of the Company’s common stock of $5.31 on September 30, 2015 . The aggregate pre-tax intrinsic value of RSUs vested during the six months ended September 30, 2015 was $8.8 million . This intrinsic value represents the fair market value of the Company’s common stock on the date of release. Employee Stock Purchase Plan Under the Company's 2012 Employee Stock Purchase Plan, or ESPP, the Company reserved 1.8 million shares for issuance. In August 2014, the Company’s stockholders approved to reserve an additional 2.0 million shares under the ESPP. Under the terms of the ESPP, eligible employees are entitled to purchase common stock, on a semi-annual basis, at a purchase price equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. At September 30, 2015 , 1.6 million shares were available for future issuance under the ESPP. Employees purchased 0.2 million shares at an average price of $4.46 and 0.2 million shares at an average price of $7.09 for the six months ended September 30, 2015 and 2014 , respectively. The intrinsic value of shares purchased during the six months ended September 30, 2015 and 2014 was $0.4 million and $0.3 million , respectively. The intrinsic value is calculated as the difference between the market value on the date of purchase and the purchase price of the shares.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Stock-based compensation cost is measured at the grant date based on the fair value of the award. The fair value of RSUs is estimated using the Company's stock price on the grant date. The fair value of options and employee stock purchase rights is estimated using the Black-Scholes model on the grant date. The Black-Scholes model determines the fair value of share-based payment awards based on assumptions including the Company's stock price on the date of grant, volatility over the term of the awards, actual and projected employee stock option exercise behaviors and risk free interest rate. The MSUs were valued using the Monte Carlo pricing model, which uses the Company's stock price, the Index value, expected volatilities of the Company's stock price and the Index, correlation coefficients and risk free interest rates to determine the fair value. The Company did not grant options during the six months ended September 30, 2015 . The fair values of the employee stock purchase rights granted are estimated as of the grant date using the Black-Scholes option-pricing model with the following assumptions: Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Expected life (years) 0.5 0.5 0.5 0.5 Risk-free interest rate 0.1 % 0.1 % 0.1 % 0.1 % Volatility 57 % 57 % 57 % 57 % Weighted average fair value $ 1.80 $ 2.57 $ 1.80 $ 2.57 The weighted average grant-date fair value per share of the RSUs awarded was $6.05 and $6.07 during the three and six months ended September 30, 2015 , respectively, as compared to $8.51 and $8.75 during the three and six months ended September 30, 2014 , respectively. The weighted average grant-date fair value per share was calculated based on the fair market value of the Company’s common stock on the respective grant dates. The following tables summarize the allocation of the stock-based compensation expense (in thousands): Stock-based compensation expense by type of grant: Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Stock options and stock purchase rights $ 289 $ 292 $ 496 $ 706 RSUs 5,650 3,936 11,547 8,720 5,939 4,228 12,043 9,426 Stock-based compensation (capitalized to) expensed from inventory (5 ) 2 (17 ) 20 Total $ 5,934 $ 4,230 $ 12,026 $ 9,446 Stock-based compensation expense by cost centers: Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Cost of revenues $ 121 $ 100 $ 226 $ 129 Research and development 3,955 2,776 8,015 6,047 Selling, general and administrative 1,863 1,352 3,802 3,250 $ 5,939 $ 4,228 $ 12,043 $ 9,426 Stock-based compensation (capitalized to) expensed from inventory (5 ) 2 (17 ) 20 Total $ 5,934 $ 4,230 $ 12,026 $ 9,446 As of September 30, 2015 , the amount of unrecognized stock-based compensation cost, net of estimated forfeitures, related to unvested stock-based awards was $25.0 million which will be recognized over a weighted average period of 1.2 years .

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Commitments The following table summarizes the Company's contractual operating leases and other purchase commitments as of September 30, 2015 (in thousands): Fiscal Years Ending March 31, Operating Leases Purchase Commitments * Total 2016 (remainder of year) $ 1,206 $ 17,898 $ 19,104 2017 2,267 4,757 7,024 2018 824 4,236 5,060 2019 472 — 472 Total minimum payments $ 4,769 $ 26,891 $ 31,660 * Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including licensed intellectual property, or IP, technology, product design, test and verification tools, of $14.4 million . Legal Proceedings The Company is currently a party to certain legal proceedings, including those noted in this section. While the Company presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm the Company's financial position, results of operations or cash flows, legal proceedings are subject to inherent uncertainties, unfavorable rulings or other events that could occur. In addition, legal proceedings are expensive to prosecute and defend against and can divert management attention and Company resources away from the Company's business objectives. Unfavorable resolutions could include monetary damages against the Company or injunctions or other restrictions on the conduct of the Company’s business, or preclude the Company from recovering the damages it seeks in legal proceedings it has commenced. It is also possible that the Company could conclude it is in the best interests of its stockholders, employees, and customers to settle one or more such matters, and any such settlement could include substantial payments or the surrender of rights to collect payments from third parties. However, the Company has not reached this conclusion with respect to any material matter at this time. In 1993, the Company was named as a Potentially Responsible Party (“PRP”) along with more than 100 other companies that used an Omega Chemical Corporation waste treatment facility in Whittier, California (the “Omega Site”). The U.S. Environmental Protection Agency (“EPA”) has alleged that Omega failed to properly treat and dispose of certain hazardous waste materials at the Omega Site. The Company is a member of a large group of PRPs, known as the Omega Chemical Site PRP Organized Group (“OPOG”), that has agreed to fund certain on-going remediation efforts relating to the Omega Site. Pursuant to a consent decree entered into between EPA and OPOG and approved by the U.S. District Court for the Central District of California (the “Court”), removal of waste materials from the Omega Site has been completed. Efforts to remediate the soil and groundwater at the Omega Site, as well as the extraction of chemical vapors from the soil and improving indoor air quality in and around the site, are still underway and are expected to be ongoing for several more years. In addition, OPOG and EPA are negotiating the remediation plan for a regional groundwater contamination plume allegedly originating at the Omega Site (the Operable Unit 2 or “OU2”). In December 2014, EPA and OPOG agreed upon the basic settlement terms and remediation actions for OU2 that will be set forth in a consent decree that once finalized will be filed with the Court. It is anticipated that Court approval of the consent decree will occur in fiscal year 2017, following which remediation of OU2 will commence. In December 2013, OPOG retained legal counsel to pursue claims against other PRPs for the regional groundwater contamination and, in December 2014, OPOG retained legal counsel to protect its interests in connection with the bankruptcy proceedings filed by an OPOG member. In November 2007, Angeles Chemical Company, located downstream from the Omega Site, filed a lawsuit (the “Angeles Litigation”) in the Court against OPOG and the PRPs for cost recovery and indemnification for future response costs allegedly resulting from OU2. In March 2008, the Court granted OPOG’s motion to stay the Angeles Litigation pending EPA’s determination of how to investigate and remediate the regional groundwater. In January 2012, as a result of challenges made by certain PRPs to the criteria previously used to allocate liability among OPOG members, and of the departure of certain PRPs from OPOG, OPOG approved changes to the cost allocation structure that resulted in an increase to the Company’s proportional allocation of liability. In addition, the subsequent departure or bankruptcy of one or more other PRPs from OPOG could have the effect of increasing the proportional liability of the remaining PRPs, including the Company. To date, the Company has remitted payments to OPOG covering its proportional allocation of liability for legal expenses and remediation costs, and the Company anticipates that its payment obligations relating to the Omega Site will increase once the OU2 consent decree is finalized. Notwithstanding such anticipated increases, the Company does not currently believe its total share of remediation-related expenses will be material to the Company’s financial statements, based on the Company’s approximately 0.5% contribution to the total waste tonnage sent to the site and current estimates of the potential aggregate remediation costs. Based on currently available information, the Company has a loss accrual that is not material and believes that the actual amount of its costs will not be materially different from the amount accrued. However, proceedings are ongoing and the eventual outcome of the clean-up efforts and the pending litigation matters is uncertain at this time. Based on currently available information, the Company does not believe that any eventual outcome will have a material adverse effect on its business or operations.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Condensed Consolidated Financial Statements include all the accounts of Applied Micro Circuits Corporation (the "Company") and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company prepared the accompanying unaudited Condensed Consolidated Financial Statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In management’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to fairly present the Company's financial position, results of operations and cash flows. Interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the Consolidated Financial Statements and notes thereto in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2015.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its: • capitalized mask sets including their useful lives, which affect cost of goods sold and property and equipment or Research and Development ("R&D") expenses, if not capitalized; • inventory valuation, warranty liabilities and revenue reserves, which affect cost of sales, gross margin, and revenues; • allowance for doubtful accounts, which affects operating expenses; • unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affect interest income (expense), net; • valuation of other long-lived assets and goodwill, which affects depreciation and impairment of long-lived assets, impairment of goodwill and apportionment of goodwill related to divestitures; • potential costs of litigation, which affect operating expenses; • valuation of deferred income taxes, which affects income tax expense (benefit); and • stock-based compensation, which affects gross margin and operating expenses. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and actual results, future results of operations will be affected.
New Accounting Pronouncements	New Accounting Pronouncements In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2014-15, "Presentation of Financial Statements-Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern", which requires an entity's management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or within one year after the date that the financial statements are available to be issued, when applicable. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating this new standard, and after adoption, it will incorporate this guidance in its assessment of going concern. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted but adoption on the original effective date is permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures.

Certain Financial Statement I17

Certain Financial Statement Information (Tables)	6 Months Ended
Certain Financial Statement Information (Tables)	Sep. 30, 2015
Certain Financial Statement Information [Abstract]
Schedule of Accounts receivable	Accounts receivable, net: September 30, March 31, (In thousands) Accounts receivable $ 12,909 $ 12,709 Less: allowance for bad debts (285 ) (302 ) $ 12,624 $ 12,407
Schedule of Inventories	Inventories: September 30, March 31, (In thousands) Finished goods $ 10,807 $ 15,310 Work in process 6,090 5,377 Raw materials 3,485 2,827 $ 20,382 $ 23,514
Schedule of Other current assets	Other current assets: September 30, March 31, (In thousands) Prepaid expenses $ 13,335 $ 14,847 Executive deferred compensation assets 942 1,004 Other 1,268 989 $ 15,545 $ 16,840
Schedule of Property and equipment	Property and equipment: Useful Life September 30, March 31, (In years) (In thousands) Machinery and equipment 3-5 $ 37,795 $ 37,286 Leasehold improvements 1-5 7,533 9,909 Computers, office furniture and equipment 3-5 33,904 32,902 79,232 80,097 Less: accumulated depreciation (64,817 ) (63,348 ) $ 14,415 $ 16,749
Schedule of Goodwill	Goodwill: September 30, March 31, (In thousands) Goodwill $ 11,425 $ 11,425
Schedule of Other assets	Other assets: September 30, March 31, (In thousands) Non-current portion of prepaid expenses $ 854 $ 1,974 Other 595 596 $ 1,449 $ 2,570
Schedule of Other accrued liabilities	Other accrued liabilities: September 30, March 31, (In thousands) Employee related liabilities $ 1,415 $ 1,454 Executive deferred compensation 984 1,025 Income taxes 304 1,311 Other 5,614 3,854 $ 8,317 $ 7,644
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments	Short-term investments: The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands): September 30, 2015 March 31, 2015 Amortized Cost Gross Unrealized Estimated Fair Value Amortized Cost Gross Unrealized Estimated Fair Value Gains Losses Gains Losses Cash $ 16,224 $ — $ — $ 16,224 $ 33,936 $ — $ — $ 33,936 Cash equivalents 4,851 — — 4,851 2,559 — — 2,559 U.S. Treasury securities and agency bonds 23,813 40 — 23,853 1,230 — — 1,230 Corporate bonds 24,515 69 (17 ) 24,567 10,772 28 (6 ) 10,794 Asset-backed securities 4,633 2 (1 ) 4,634 — 15 — 15 Municipal bonds 1,353 2 — 1,355 — — — — Mutual funds — — — — 24,895 1,955 (59 ) 26,791 Preferred stock 5 11 — 16 11 22 — 33 $ 75,394 $ 124 $ (18 ) $ 75,500 $ 73,403 $ 2,020 $ (65 ) $ 75,358 Reported as: Cash and cash equivalents $ 21,075 $ 36,495 Short-term investments available-for-sale 54,425 38,863 $ 75,500 $ 75,358
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments measured at fair value on recurring basis	The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands): September 30, 2015 March 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash $ 16,224 $ — $ — $ 16,224 $ 33,936 $ — $ — $ 33,936 Cash equivalents 4,851 — — 4,851 2,559 — — 2,559 U.S. Treasury securities and agency bonds 23,853 — — 23,853 1,230 — — 1,230 Corporate bonds — 24,567 — 24,567 — 10,794 — 10,794 Asset-backed securities — 4,634 — 4,634 — 15 — 15 Municipal bonds 1,355 — — 1,355 — — — — Mutual funds — — — — 26,791 — — 26,791 Preferred stock — 16 — 16 — 33 — 33 $ 46,283 $ 29,217 $ — $ 75,500 $ 64,516 $ 10,842 $ — $ 75,358
Schedule of Cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity	The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds, asset-backed securities and municipal bonds, by contractual maturity (in thousands): September 30, 2015 Cost Estimated Fair Value Less than 1 year $ 11,574 $ 11,583 Mature in 1 – 2 years 31,700 31,730 Mature in 3 – 5 years 11,040 11,096 Mature after 5 years — — $ 54,314 $ 54,409
Schedule of Gross unrealized losses	The following is a summary of gross unrealized losses (in thousands): As of September 30, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses U.S. Treasury securities and agency bonds $ 1,579 $ — $ — $ — $ 1,579 $ — Corporate bonds 6,617 (17 ) — — 6,617 (17 ) Asset-backed securities 1,404 (1 ) — — 1,404 (1 ) $ 9,600 $ (18 ) $ — $ — $ 9,600 $ (18 ) As of March 31, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate bonds $ 878 $ (6 ) $ — $ — $ 878 $ (6 ) Mutual funds 14,592 (17 ) 475 (42 ) 15,067 (59 ) $ 15,470 $ (23 ) $ 475 $ (42 ) $ 15,945 $ (65 )
Schedule of Warranty reserve activity	The following table summarizes warranty reserve activities (in thousands): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Beginning balance $ 222 $ 177 $ 194 $ 199 Additions during the period 72 6 129 — Settlements and expirations (25 ) (8 ) (53 ) (23 ) Change in estimates (9 ) — (10 ) (1 ) Ending balance $ 260 $ 175 $ 260 $ 175
Schedule of Interest income, net	Realized gain on short-term investments and interest income, net (in thousands): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Net realized gain on short-term investments $ 127 $ 5 $ 1,557 $ — Interest income, net 130 388 319 729 $ 257 $ 393 $ 1,876 $ 729
Schedule of Reconciliation of shares used to calculate basic and diluted net loss per share	The reconciliation of shares used to calculate basic and diluted net loss per share consists of the following (in thousands, except per share data): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Net loss $ (8,061 ) $ (11,717 ) $ (15,465 ) $ (24,782 ) Shares used in net loss per share computation: Weighted average common shares outstanding, basic 82,176 78,487 81,680 78,202 Net effect of dilutive common share equivalents — — — — Weighted average common shares outstanding, diluted 82,176 78,487 81,680 78,202 Basic and diluted net loss per share $ (0.10 ) $ (0.15 ) $ (0.19 ) $ (0.32 )

Restructuring Charges (Tables)

Restructuring Charges (Tables)	6 Months Ended
Restructuring Charges (Tables)	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Schedule of restructuring activity	The following table sets forth a summary of restructuring activities related to the Company's restructuring plan described above (in thousands): Workforce Reduction Operating Lease Commitments Other Total Liability, March 31, 2015 $ 449 $ 113 $ 15 $ 577 Restructuring charges 109 — 2 111 Cash payments (270 ) (41 ) (9 ) (320 ) Non-cash items (14 ) 12 — (2 ) Liability, September 30, 2015 $ 274 $ 84 $ 8 $ 366

Veloce (Tables)

Veloce (Tables)	6 Months Ended
Veloce (Tables)	Sep. 30, 2015
Business Combinations [Abstract]
Schedule of cash payments and stock issuance activities	The following table summarizes the cash payment and stock issuance activities during the three and six months ended September 30, 2015 and 2014 as part of the above arrangement (in thousands): Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Cash payments $ 25 $ 1,116 $ 90 $ 7,499 Value of common stock issued 1,947 281 2,868 615 Total payments $ 1,972 $ 1,397 $ 2,958 $ 8,114 Shares of common stock issued 354 38 517 77

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2015
Equity [Abstract]
Schedule of Option Activity Under Stock Incentive Plans	A summary of the Company's stock option activities and related information during the six months ended September 30, 2015 is as follows: Number of Shares (thousands) Weighted Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value (millions) Outstanding at the beginning of the year 1,794 $ 9.15 Granted — — Exercised (25 ) $ 5.23 — (1 ) Cancelled (99 ) $ 10.65 Outstanding at the end of the period 1,670 $ 9.12 1.4 $ — (2 ) Vested and expected to vest at the end of the period 1,670 $ 9.12 1.4 $ — (2 ) Vested and exercisable at the end of the period 1,670 $ 9.12 1.4 $ — (2 ) (1) The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. (2) The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of September 30, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $5.31 per share on September 30, 2015 .
Schedule of Restricted Stock Unit Activity	RSU activities during the six months ended September 30, 2015 is set forth below (in thousands): Number of Shares Outstanding at the beginning of the year 4,328 Awarded 1,474 Vested (1,462 ) Cancelled (342 ) Outstanding at the end of the period 3,998

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used	The fair values of the employee stock purchase rights granted are estimated as of the grant date using the Black-Scholes option-pricing model with the following assumptions: Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Expected life (years) 0.5 0.5 0.5 0.5 Risk-free interest rate 0.1 % 0.1 % 0.1 % 0.1 % Volatility 57 % 57 % 57 % 57 % Weighted average fair value $ 1.80 $ 2.57 $ 1.80 $ 2.57
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units	The following tables summarize the allocation of the stock-based compensation expense (in thousands): Stock-based compensation expense by type of grant: Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Stock options and stock purchase rights $ 289 $ 292 $ 496 $ 706 RSUs 5,650 3,936 11,547 8,720 5,939 4,228 12,043 9,426 Stock-based compensation (capitalized to) expensed from inventory (5 ) 2 (17 ) 20 Total $ 5,934 $ 4,230 $ 12,026 $ 9,446
Summary of Stock-Based Compensation Expense	Stock-based compensation expense by cost centers: Three Months Ended September 30, Six Months Ended September 30, 2015 2014 2015 2014 Cost of revenues $ 121 $ 100 $ 226 $ 129 Research and development 3,955 2,776 8,015 6,047 Selling, general and administrative 1,863 1,352 3,802 3,250 $ 5,939 $ 4,228 $ 12,043 $ 9,426 Stock-based compensation (capitalized to) expensed from inventory (5 ) 2 (17 ) 20 Total $ 5,934 $ 4,230 $ 12,026 $ 9,446

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
Commitments and Contingencies (Tables)	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contractual Obligation by Fiscal Year Maturity	The following table summarizes the Company's contractual operating leases and other purchase commitments as of September 30, 2015 (in thousands): Fiscal Years Ending March 31, Operating Leases Purchase Commitments * Total 2016 (remainder of year) $ 1,206 $ 17,898 $ 19,104 2017 2,267 4,757 7,024 2018 824 4,236 5,060 2019 472 — 472 Total minimum payments $ 4,769 $ 26,891 $ 31,660 * Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including licensed intellectual property, or IP, technology, product design, test and verification tools, of $14.4 million .

Certain Financial Statement I23

Certain Financial Statement Information - Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Schedule of Accounts receivable
Accounts receivable	$ 12,909	$ 12,709
Less: allowance for bad debts	(285)	(302)
Accounts receivable, net	$ 12,624	$ 12,407	[1]

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Certain Financial Statement I24

Certain Financial Statement Information - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Schedule of Inventories
Finished goods	$ 10,807	$ 15,310
Work in process	6,090	5,377
Raw materials	3,485	2,827
Inventories, total	$ 20,382	$ 23,514	[1]

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Certain Financial Statement I25

Certain Financial Statement Information - Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Schedule of Other current assets
Prepaid expenses	$ 13,335	$ 14,847
Executive deferred compensation assets	942	1,004
Other	1,268	989
Other current assets, total	$ 15,545	$ 16,840	[1]

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Certain Financial Statement I26

Certain Financial Statement Information - Property and Equipment (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2015	Mar. 31, 2015
Schedule of Property and equipment
Machinery and equipment	$ 37,795	$ 37,286
Leasehold improvements	7,533	9,909
Computers, office furniture and equipment	33,904	32,902
Property and equipment, gross	79,232	80,097
Less: accumulated depreciation	(64,817)	(63,348)
Property and equipment, net	$ 14,415	$ 16,749	[1]
Machinery and Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Machinery and Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Leasehold Improvements \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	1 year
Leasehold Improvements \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Computers, Office Furniture and Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Computers, Office Furniture and Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Certain Financial Statement I27

Certain Financial Statement Information - Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Certain Financial Statement Information [Abstract]
Goodwill	$ 11,425	$ 11,425	[1]

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Certain Financial Statement I28

Certain Financial Statement Information - Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Schedule of other assets
Non-current portion of prepaid expenses	$ 854	$ 1,974
Other	595	596
Total other assets	$ 1,449	$ 2,570	[1]

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Certain Financial Statement I29

Certain Financial Statement Information - Other Accrued Liabiliteis (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Schedule of other accrued liabilities
Employee related liabilities	$ 1,415	$ 1,454
Executive deferred compensation	984	1,025
Income taxes	304	1,311
Other	5,614	3,854
Total other accrued liabilities	$ 8,317	$ 7,644	[1]

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

Certain Financial Statement I30

Certain Financial Statement Information - Short-Term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015		Sep. 30, 2014	[2]	Mar. 31, 2014	[2]
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	$ 75,394	$ 73,403
Available-for-sale Securities, Gross Unrealized Gains	124	2,020
Available-for-sale Securities, Gross Unrealized Losses	(18)	(65)
Available-for-sale Securities, Estimated Fair Value	75,500	75,358
Cash and cash equivalents	21,075	36,495	[1]	$ 53,946		$ 71,539
Short-term investments available-for-sale	54,425	38,863	[1]
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	75,500	75,358
Cash
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Cash and Cash equivalents, Estimated Fair Value	16,224	33,936
Cash equivalents
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Cash and Cash equivalents, Estimated Fair Value	4,851	2,559
U.S Treasury securities and agency bonds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	23,813	1,230
Available-for-sale Securities, Gross Unrealized Gains	40	0
Available-for-sale Securities, Gross Unrealized Losses	0	0
Available-for-sale Securities, Estimated Fair Value	23,853	1,230
Corporate bonds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	24,515	10,772
Available-for-sale Securities, Gross Unrealized Gains	69	28
Available-for-sale Securities, Gross Unrealized Losses	(17)	(6)
Available-for-sale Securities, Estimated Fair Value	24,567	10,794
Asset-backed securities
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	4,633	0
Available-for-sale Securities, Gross Unrealized Gains	2	15
Available-for-sale Securities, Gross Unrealized Losses	(1)	0
Available-for-sale Securities, Estimated Fair Value	4,634	15
Municipal bonds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	1,353	0
Available-for-sale Securities, Gross Unrealized Gains	2	0
Available-for-sale Securities, Gross Unrealized Losses	0	0
Available-for-sale Securities, Estimated Fair Value	1,355	0
Mutual Funds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	0	24,895
Available-for-sale Securities, Gross Unrealized Gains	0	1,955
Available-for-sale Securities, Gross Unrealized Losses	0	(59)
Available-for-sale Securities, Estimated Fair Value	0	26,791
Preferred stock
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	5	11
Available-for-sale Securities, Gross Unrealized Gains	11	22
Available-for-sale Securities, Gross Unrealized Losses	0	0
Available-for-sale Securities, Estimated Fair Value	$ 16	$ 33

[1]	The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.
[2]	The Statement of Cash Flows for the six months ended September 30, 2014 reflects an immaterial revision to correct outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities. As a result, net cash used for operating activities increased by $0.3 million and net cash used for investing activities decreased by the corresponding amount.

Certain Financial Statement I31

Certain Financial Statement Information - Short Term Investments Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	$ 75,500	$ 75,358
Cash
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	16,224	33,936
Cash equivalents
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	4,851	2,559
U.S Treasury securities and agency bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	23,853	1,230
Corporate bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	24,567	10,794
Asset-backed securities
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	4,634	15
Municipal bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	1,355	0
Mutual Funds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	26,791
Preferred stock
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	16	33
Recurring
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	75,500	75,358
Recurring \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	46,283	64,516
Recurring \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	29,217	10,842
Recurring \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	0	0
Recurring \| Cash
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	16,224	33,936
Recurring \| Cash \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	16,224	33,936
Recurring \| Cash \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	0	0
Recurring \| Cash \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	0	0
Recurring \| Cash equivalents
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	4,851	2,559
Recurring \| Cash equivalents \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	4,851	2,559
Recurring \| Cash equivalents \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	0	0
Recurring \| Cash equivalents \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	0	0
Recurring \| U.S Treasury securities and agency bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	23,853	1,230
Recurring \| U.S Treasury securities and agency bonds \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	23,853	1,230
Recurring \| U.S Treasury securities and agency bonds \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| U.S Treasury securities and agency bonds \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Corporate bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	24,567	10,794
Recurring \| Corporate bonds \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Corporate bonds \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	24,567	10,794
Recurring \| Corporate bonds \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Asset-backed securities
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	4,634	15
Recurring \| Asset-backed securities \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Asset-backed securities \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	4,634	15
Recurring \| Asset-backed securities \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Municipal bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	1,355	0
Recurring \| Municipal bonds \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	1,355	0
Recurring \| Municipal bonds \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Municipal bonds \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Mutual Funds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	26,791
Recurring \| Mutual Funds \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	26,791
Recurring \| Mutual Funds \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Mutual Funds \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Preferred stock
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	16	33
Recurring \| Preferred stock \| Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring \| Preferred stock \| Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	16	33
Recurring \| Preferred stock \| Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	$ 0	$ 0

Certain Financial Statement I32

Certain Financial Statement Information - Short-Term Investments Schedule of Maturities (Details) $ in Thousands	Sep. 30, 2015USD ($)
Schedule of cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity
Less than 1 year, Cost	$ 11,574
Mature in 1 - 2 years, Cost	31,700
Mature in 3 - 5 years, Cost	11,040
Mature after 5 years, Cost	0
Cost, Total	54,314
Less than 1 year, Fair Value	11,583
Mature in 1 - 2 years, Fair Value	31,730
Mature in 3 - 5 years, Fair Value	11,096
Mature after 5 years, Fair Value	0
Fair Value, Total	$ 54,409

Certain Financial Statement I33

Certain Financial Statement Information - Short-Term Investments Gross Unrealized Losses (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	$ 9,600	$ 15,470
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(18)	(23)
12 Months or More of Unrealized Losses, Estimated Fair Value	0	475
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0	(42)
Total, Estimated Fair Value	9,600	15,945
Total Gross Unrealized Losses	(18)	(65)
U.S. Treasury securities and agency bonds
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	1,579
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	0
12 Months or More of Unrealized Losses, Estimated Fair Value	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0
Total, Estimated Fair Value	1,579
Total Gross Unrealized Losses	0
Corporate bonds
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	6,617	878
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(17)	(6)
12 Months or More of Unrealized Losses, Estimated Fair Value	0	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0	0
Total, Estimated Fair Value	6,617	878
Total Gross Unrealized Losses	(17)	(6)
Asset-backed securities
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	1,404
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(1)
12 Months or More of Unrealized Losses, Estimated Fair Value	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0
Total, Estimated Fair Value	1,404
Total Gross Unrealized Losses	$ (1)
Mutual Funds
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value		14,592
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses		(17)
12 Months or More of Unrealized Losses, Estimated Fair Value		475
12 Months or More of Unrealized Losses, Gross Unrealized Losses		(42)
Total, Estimated Fair Value		15,067
Total Gross Unrealized Losses		$ (59)

Certain Financial Statement I34

Certain Financial Statement Information - Warranty (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule of Warranty Reserve Activity
Beginning balance	$ 222	$ 177	$ 194	$ 199
Additions during the period	72	6	129	0
Settlements and expirations	(25)	(8)	(53)	(23)
Change in estimates	(9)	0	(10)	(1)
Ending balance	$ 260	$ 175	$ 260	$ 175

Certain Financial Statement I35

Certain Financial Statement Information - Realized Gain on Short-Term Investments and Interest Income, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule of Interest Income, Net
Net realized gain on short-term investments	$ 127	$ 5	$ 1,557	$ 0
Interest income, net	130	388	319	729
Realized gain on short-term investments and interest income, net	$ 257	$ 393	$ 1,876	$ 729

Certain Financial Statement I36

Certain Financial Statement Information - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule of Reconciliation of Shares Used to Calculate Basic and Diluted Net (Loss) Income Per Share
Net loss	$ (8,061)	$ (11,717)	$ (15,465)	$ (24,782)	[1]
Shares used in net loss per share computation:
Weighted average common shares outstanding, basic (shares)	82,176	78,487	81,680	78,202
Net effect of dilutive common share equivalents (shares)	0	0	0	0
Weighted average common shares outstanding, diluted (shares)	82,176	78,487	81,680	78,202
Basic and diluted net loss per share (in dollars per share)	$ (0.10)	$ (0.15)	$ (0.19)	$ (0.32)

[1]	The Statement of Cash Flows for the six months ended September 30, 2014 reflects an immaterial revision to correct outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities. As a result, net cash used for operating activities increased by $0.3 million and net cash used for investing activities decreased by the corresponding amount.

Certain Financial Statement I37

Certain Financial Statement Information - Additional Information (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Options and Restricted Stock Units
Certain Financial Statement Information [Line Items]
Dilutive securities excluded from the net loss per share computation	3.5	1	3.6	1.2

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Details) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended
	Jan. 31, 2015employee	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 15	$ (110)	$ 111	$ 1,101
Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated \| employee	40
Number of positions expected to be eliminated (percent)	7.00%
Restructuring charges						$ 4,200

Restructuring Charges - Restruc

Restructuring Charges - Restructuring Activities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Reserve [Roll Forward]
Liability, beginning balance			$ 577
Restructuring charges	$ 15	$ (110)	111	$ 1,101
Cash payments			(320)
Non-cash items			(2)
Liability, ending balance	366		366
Workforce Reduction [Member]
Restructuring Reserve [Roll Forward]
Liability, beginning balance			449
Restructuring charges			109
Cash payments			(270)
Non-cash items			(14)
Liability, ending balance	274		274
Operating Lease Commitments [Member]
Restructuring Reserve [Roll Forward]
Liability, beginning balance			113
Restructuring charges			0
Cash payments			(41)
Non-cash items			12
Liability, ending balance	84		84
Other [Member]
Restructuring Reserve [Roll Forward]
Liability, beginning balance			15
Restructuring charges			2
Cash payments			(9)
Non-cash items			0
Liability, ending balance	$ 8		$ 8

Veloce - Additional Information

Veloce - Additional Information (Details) - Veloce Technologies Inc - USD ($) shares in Thousands, $ in Thousands	Jun. 20, 2012	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015
Business Acquisition [Line Items]
Total purchase consideration	$ 178,500	$ 1,972	$ 1,397	$ 2,958	$ 8,114	$ 171,900
Cash payments		$ 25	$ 1,116	$ 90	$ 7,499	$ 89,400
Stock issued (in shares)		354	38	517	77	11,200
Cash and stock to be paid in next period		$ 1,100		$ 1,100		$ 1,100
Total equity value transferred						82,500
Consideration payable in cash or equity		$ 6,600		$ 6,600		$ 6,600

Veloce - Cash Payments and Stoc

Veloce - Cash Payments and Stock Issuances (Details) - Veloce Technologies Inc - USD ($) shares in Thousands, $ in Thousands	Jun. 20, 2012	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015
Business Acquisition [Line Items]
Cash payments		$ 25	$ 1,116	$ 90	$ 7,499	$ 89,400
Value of common stock issued		1,947	281	2,868	615
Total payments	$ 178,500	$ 1,972	$ 1,397	$ 2,958	$ 8,114	$ 171,900
Shares of common stock issued (in shares)		354	38	517	77	11,200

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Sep. 30, 2015USD ($)Approved_Plan$ / sharesshares
Equity [Abstract]
Number of stockholder-approved plans \| Approved_Plan	2
Number of plans unapproved by stockholders \| Approved_Plan	1
Schedule of Option Activity Under Stock Incentive Plans
Number of Shares, Outstanding at the beginning of the year (in shares) \| shares	1,794
Number of Shares, Granted (in shares) \| shares	0
Number of Shares, Exercised (in shares) \| shares	(25)
Number of Shares, Forfeited (in shares) \| shares	(99)
Number of Shares, Outstanding at the end of the period (in shares) \| shares	1,670
Number of Shares, Vested at the end of the period (in shares) \| shares	1,670
Number of Shares, Vested and exercisable at end of period (in shares) \| shares	1,670
Schedule of Weighted Average Exercise Price Per Share Under Stock Incentive Plans
Weighted Average Exercise Price Per Share, Outstanding at the beginning of the year (USD per share)	$ 9.15
Weighted Average Exercise Price Per Share, Granted (USD per share)	0
Weighted Average Exercise Price Per Share, Exercised (USD per share)	5.23
Weighted Average Exercise Price Per Share, Forfeited (USD per share)	10.65
Weighted Average Exercise Price Per Share, Outstanding at the end of the period (USD per share)	9.12
Weighted Average Exercise Price Per Share, Vested at the end of the period (USD per share)	9.12
Weighted Average Exercise Price Per Share, Vested and exercisable at the end of the period (USD per share)	$ 9.12
Weighted average remaining contractual term for options outstanding at end of period (in years)	1 year 4 months 24 days
Weighted Average Remaining Contractual Life, Vested and Exercisable at Period End (in years)	1 year 4 months 24 days
Weighted Average Remaining Contractual Life, Vested and expected to vest at end of period (in years)	1 year 4 months 24 days
Aggregate pretax intrinsic value of options exercised \| $	$ 0	[1]
Aggregate intrinsic value of options outstanding at end of period \| $	0	[2]
Aggregate intrinsic value of options, Vested and exercisable at end of period \| $	0	[2]
Aggregate intrinsic value of options, Vested and expected to vest at end of period \| $	$ 0	[2]
Common stock, closing price per share (USD per share)	$ 5.31

[1]	The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares.
[2]	The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of September 30, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $5.31 per share on September 30, 2015.

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Units (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		18 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Oct. 31, 2014
Class of Stock [Line Items]
Stock-based compensation expense recognized		$ 5,939	$ 4,228	$ 12,043	$ 9,426
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Weighted average remaining contractual term for the restricted stock units outstanding (in years)				1 year 2 months 10 days
Aggregate pre-tax intrinsic value of restricted stock units outstanding which includes performance based awards which are subject to milestone attainments		$ 21,200		$ 21,200
Common stock, closing price per share (USD per share)		$ 5.31		$ 5.31
Aggregate pretax intrinsic value		$ 8,800		$ 8,800
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Stock-based compensation expense recognized		$ 5,650	$ 3,936	$ 11,547	$ 8,720
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Shares, Beginning balance (in shares)				4,328
Number of Shares, Awarded (in shares)				1,474
Number of Shares, Vested (in shares)				(1,462)
Number of Shares, Cancelled (in shares)				(342)
Number of Shares, Ending balance (in shares)	4,328	3,998		3,998
Performance-Based MSU
Class of Stock [Line Items]
Grants in period, fair value						$ 4,500
Value of shares expired unvested in period		$ 1,300		$ 1,300
Performance-Based MSU \| Minimum
Class of Stock [Line Items]
Vesting percentage				0.00%
Performance-Based MSU \| Maximum
Class of Stock [Line Items]
Vesting percentage				150.00%
Performance-Based MSU \| First Vesting period
Class of Stock [Line Items]
Award performance period				2 years
Performance-Based MSU \| Second Vesting Period
Class of Stock [Line Items]
Award performance period				3 years
1992 Equity Incentive Plan \| Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Vesting period, in years				4 years
1992 Equity Incentive Plan \| Restricted Stock Units (RSUs) \| First Vesting period
Class of Stock [Line Items]
Vesting percentage				25.00%
2011 Equity Incentive Plan \| Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Vesting period, in years				4 years
2011 Equity Incentive Plan \| Restricted Stock Units (RSUs) \| First Vesting period
Class of Stock [Line Items]
Vesting percentage				25.00%
FY2016 Short-Term Incentive Plan \| Minimum
Class of Stock [Line Items]
Award pay out percentage				50.00%
FY2016 Short-Term Incentive Plan \| Maximum
Class of Stock [Line Items]
Award pay out percentage				150.00%
Incentive Compensation Program
Class of Stock [Line Items]
Vesting period, in years	1 year
Value of program		$ 6,700		$ 6,700
Stock-based compensation expense recognized				$ 3,300

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - 2012 Employee Stock Purchase Plan - USD ($) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014	Aug. 30, 2012
Class of Stock [Line Items]
Common stock reserved for issuance (in shares)				1.8
Additional shares reserved for issuance (in shares)			2
Percentage of purchase price of common stock equal to fair market value	85.00%
Shares available for future issuance (in shares)	1.6
Average purchase price of shares purchased (in dollars per share)	$ 4.46	$ 7.09
Number of shares purchased (in shares)	0.2	0.2
Intrinsic value of shares purchased	$ 0.4	$ 0.3

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value Assumptions (Details) - Employee Stock Purchase Plan - $ / shares	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	6 months	6 months	6 months	6 months
Risk-free interest rate	0.10%	0.10%	0.10%	0.10%
Volatility	57.00%	57.00%	57.00%	57.00%
Weighted average fair value	$ 1.80	$ 2.57	$ 1.80	$ 2.57

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	$ 5,939	$ 4,228	$ 12,043	$ 9,426
Stock-based compensation (capitalized to) expensed from inventory	(5)	2	(17)	20
Total	5,934	4,230	12,026	9,446
Cost of Revenues
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	121	100	226	129
Research and Development Expense
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	3,955	2,776	8,015	6,047
Selling, General and Administrative
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	1,863	1,352	3,802	3,250
Stock Options
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	289	292	496	706
Restricted Stock Units (RSUs)
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	$ 5,650	$ 3,936	$ 11,547	$ 8,720

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant-date fair value per share of the restricted stock units awarded	$ 6.05	$ 8.51	$ 6.07	$ 8.75
Unearned stock-based compensation	$ 25		$ 25
Weighted-average period over which the unearned stock-based compensation is expected to be recognized, years			1 year 2 months

Commitments and Contingencies -

Commitments and Contingencies - Commitments (Details) $ in Thousands	Sep. 30, 2015USD ($)
Operating Leases
2016 (remainder of year)	$ 1,206
2,017	2,267
2,018	824
2,019	472
Total minimum payments	4,769
Purchase Commitments
2016 (remainder of year)	17,898	[1]
2,017	4,757	[1]
2,018	4,236	[1]
2,019	0	[1]
Total minimum payments	26,891	[1]
Total
2016 (remainder of year)	19,104
2,017	7,024
2,018	5,060
2,019	472
Total minimum payments	31,660
Licensing Costs Due	$ 14,400

[1]	Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including licensed intellectual property, or IP, technology, product design, test and verification tools, of $14.4 million.

Commitments and Contingencies49

Commitments and Contingencies - Contingencies (Details) - Company	1 Months Ended	6 Months Ended
	Jan. 31, 2012	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Companies named as Potentially Responsible Parties (more than)		100
Percent of contribution to the total waste	0.50%